Market news — every asset we track

Assets

PLRZ

Polyrizon enrolls first patient in U.S. allergy blocker trial

Sep 22Investing.com

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued to a single institutional investor Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also i

Sep 4Yahoo Finance

PLRZ

Polyrizon raises $4 million in registered direct offering

Sep 3Investing.com

PLRZ

Polyrizon completes contracting for allergy blocker trial sites

Sep 2Investing.com

PLRZ

Polyrizon completes contracting with all five clinical sites

Aug 20Investing.com

PLRZ

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment